Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Activated carbon cryogels and related methods
Image sensor with improved color crosstalk
Methods, systems and computer program products for importing data from an edge router to a network management system
Switching element for a valve train of an internal combustion engine
Methods of isolating bipotent hepatic progenitor cells
Method of making and using an alpha-glucanase composition to reduce or remove biofilm
Multi-dimensional credibility scoring
  Randomly Featured Patents
Self-supporting aluminum titanate composites and products relating thereto
Method and apparatus for managing power consumption in data processing systems
Power-on-reset circuit and reset method
Combination tree stand and wheeled game carrier
Saddle-type vehicle equipped with a navigation system
Cover unit for ceiling rails
Identifiers for digital media
Baby formula preparation system
Gaming apparatus having memory fault detection
Cellulosic ultrafiltration membrane